Rep. Chris Collins tells constituents he will "actively campaign" for Congress

I will work to ensure the 27th Congressional District remains in Republican hands

September 19, 2018 - 3:24 pm

Buffalo, N.Y. (WBEN) - Just days after it was revealed he will remain on the November ballot in the NY27 Congressional district, Rep. Chris Collins has emailed constituents indicating he will "actively campaign" for his seat.

Following is the complete text from the email.

My friends,  

Voters can be assured that with the recent turn of events, they can count on me to actively campaign for Congress, and to serve should voters re-elect me. 

The stakes are too high to allow the radical left to take control of this seat in Congress.  Their agenda is clear.  They want to reverse the recently enacted tax cuts, impose Canadian style healthcare, inflict new job-killing regulations and impeach President Trump.  

We cannot stand by and let that happen.

As a result, I will fight on two fronts.  I will work to ensure the 27th Congressional District remains in Republican hands, while I fight to clear my good name in the courts.

On Monday, Erie County Republican Party Chairman Nick Langworthy announced Collins was no longer cooperating in efforts to remove himself from the ballot, essentially ending what became known as "the race to repolace" in NY27.  Collins will face Democratic challenger Nathan McMurray in the November general election for the Congressional seat.

Collins was indicted last month by a federal grand jury of conspiracy to commit securities fraud.

Collins, along with his son Cameron, and Cameron's future father-in-law Stephen Zarsky, were accused of insider trading related to the Australian biotechnology company Innate Immunotherapeutics Limited.

The indictment alleged that in June of 2017, Congressman Collins violated the duties he owed to the biotechnology company by passing material, nonpublic information regarding the drug trial results to his son so that Cameron could use that information to make timely trades in Innate stock and tip others. Cameron Collins allegedly traded on that information and passed it to Zarsky, who then sent it to other defendants who were not named. The trading allowed the individuals involved to avoid over $768,000 in losses that they would have otherwise incurred if they sold their stocks in Innate after the drug trial results became public.

In his statement to constituents Wednesday, Collins vows to fight to clear his name.


Comments ()